Hola,
¿eres nuevo aquí?

Regístrate gratis y conecta tu empresa con financiación pública, partners y proyectos.

Tengo cuenta

Regístrate

Ver video

PRISAR

Financiado

Cerrado

Preclinical Intra Operative Image Guided Surgery and Post Operative Radiotherapy...

Preclinical Intra Operative Image Guided Surgery and Post Operative Radiotherapy of Tumours The main objective and basic concept of our proposal is to improve intra-operative and post-operative targeted surgical probes and new detection systems for surgical intervention of cancer. The work revolves around the mobility of... ver más

31/01/2019

PERC

2M€

Presupuesto del proyecto: 2M€

Líder del proyecto

PERCUROS BV No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Fecha límite participación Sin fecha límite de participación.

Ver 14 Participantes

Financiación concedida El organismo H2020 notifico la concesión del proyecto el día 2019-01-31

MSCA-RISE-2014: Marie Skłodowska-Curie Research and...

I+D

Cerrada hace 10 años

0% 100% 100%

Información adicional privada

No hay información privada compartida para este proyecto. Habla con el coordinador.

14 Participantes

PERC

378.00K€ | Lider

RAYFOS LTD

216.00K€ | Participante

MKT

108.00K€ | Participante

UNIVERSITEIT MAASTRICHT

162.00K€ | Participante

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Proyectos interesantes

PRISAR2 proactive monitoring of cancer as an alternative to surgery 2M€ Cerrado

TRIOP TRIOP: an intraoperative probe to assess tumor margins and r... 75K€ Cerrado

IMAGIO IMAGING AND ADVANCED GUIDANCE FOR WORKFLOW OPTIMIZATION IN I... 37M€ Cerrado

PROSENSE Cancer Diagnosis Parallel Sensing of Prostate Cancer Biomar... 4M€ Cerrado

ENDOIMAGE Activatable Fluorescent Probes as Smart Diagnostic Tools for... 100K€ Cerrado

CerISMA Cerenkov Imaging for Surgical Margin Assessment 2M€ Cerrado

Duración del proyecto: 49 meses Fecha Inicio: 2014-12-01
Fecha Fin: 2019-01-31

Líder del proyecto

PERCUROS BV No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Presupuesto del proyecto 2M€

Fecha límite de participación Sin fecha límite de participación.

Descripción del proyecto The main objective and basic concept of our proposal is to improve intra-operative and post-operative targeted surgical probes and new detection systems for surgical intervention of cancer. The work revolves around the mobility of clinicians, scientists and technologists between twelve consortium partners and across four different countries. The goal is the implementation of inter-disciplinary, inter-sector, cross-training of personnel. As a consequence, this will serve to accelerate the development of improved imaging technologies and hybrid fluorescence/radionuclide probes for the surgical intervention of cancer. The hypothesis is that if we can develop a hybrid probe for both targeted image-guided surgery and post-operative molecular radiotherapy, we would be implementing a revolutionary imaging and therapeutic approach for oncology surgeons to help their patients by improving better overall survival and quality of life for the patient. There are four key objectives within this project: 1) synthesis of a near infra-red fluorescence (NIRF)-dye conjugated to a peptide that is targeted towards a tumour associated antigen, 2) deliver a novel clinical optoacoustic handheld camera to detect the fluorescence probe in deep tissue, 3) validate the probe/target combination across the subcellular, cellular, endoscopic and macroscopic levels with state-of-art technologies, and 4) develop the probe further by targeting a radionuclide entity to the fluorescent construct for postoperative radiotherapy. Surgeons would have a more definitive reference for resection, if the tumour margin can be clearly defined. If this can be achieved, the impact would be (a) reduced recurrence rates in patients by lowering the risk of residual tumour tissue remaining after surgery and as a consequence improve survival, (b) minimised removal of healthy tissues, c) reduced patient morbidity and hospital stay and d) significant health cost benefits.

Conecta tu I+D

Entra hoy

¿Olvidé mi contraseña?

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores